# TRAF7

Source: https://onco.cc/targets/traf7/  
OnCo record `traf7` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TRAF7 (E3 ubiquitin-protein ligase TRAF7) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma, Skin cancer, Pleural mesothelioma and 1 more.

## Summary

E3 ubiquitin and SUMO-protein ligase that plays a role in different biological processes such as innate immunity, inflammation or apoptosis. Potentiates MAP3K3-mediated activation of JUN/AP1 and DDIT3 transcriptional regulators. Negatively regulates MYB transcriptional activity by sequestering it to the cytosol via SUMOylation.

Open Targets scores its association with cancer at 0.62 (direct and indirect evidence; datatypes literature 0.83, animal model 0.60, genetic association 0.00, somatic mutation 0.96). IntOGen calls it a driver in 2 cohorts (2 activating, 0 loss-of-function), covering Pleural Mesothelioma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: TNF receptor associated factor 7; E3 ubiquitin-protein ligase TRAF7; RNF119; DKFZp586I021; MGC7807; RFWD1
- Tags: cancer-genes-wave
- Symbol: TRAF7
- Class: oncogene
- Biology: E3 ubiquitin and SUMO-protein ligase that plays a role in different biological processes such as innate immunity, inflammation or apoptosis. Potentiates MAP3K3-mediated activation of JUN/AP1 and DDIT3 transcriptional regulators. Negatively regulates MYB transcriptional activity by sequestering it to the cytosol via SUMOylation. Plays a role in the phosphorylation of MAPK1 and/or MAPK3, probably via its interaction with MAP3K3. Negatively regulates RLR-mediated innate immunity by promoting 'Lys-48'-linked ubiquitination of TBK1 through its RING domain to inhibit the cellular antiviral response. Promotes 'Lys-29'-linked polyubiquitination of NEMO/IKBKG and RELA leading to targeting these two proteins to lysosomal degradative pathways, reducing the transcriptional activity of NF-kappa-B. Location: Cytoplasmic vesicle; Cytoplasm; Nucleus (UniProt). Locus 16p13.3 (HGNC).
- Where found: Mesothelioma: IntOGen driver in 2 cohorts (PLMESO); Skin cancer: Open Targets association 0.54 with skin cancer (MONDO_0002898); Pleural mesothelioma: IntOGen driver in 2 cohorts (PLMESO); Melanoma: Open Targets association 0.52 with melanoma (MONDO_0005105)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 2 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:20456: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20456
- UniProt Q6Q0C0: https://www.uniprot.org/uniprotkb/Q6Q0C0/entry
- NCBI Gene 84231: https://www.ncbi.nlm.nih.gov/gene/84231
- Ensembl ENSG00000131653: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131653

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Mesothelioma](https://onco.cc/cancers/mesothelioma/), [Pleural mesothelioma](https://onco.cc/cancers/pleural-mesothelioma/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/traf7.json